Observational studyThe journal of pathology. Clinical research2026
Systemic and local decorin levels mirror the clinical course of pancreatic cancer.
Observational study in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite significant progress in oncology research, pancreatic cancer remains inherently difficult to treat, and the mechanisms underlying therapeutic resistance remain unresolved. Decorin (DCN), a member of the family of small leucine-rich proteoglycans, has emerged as a versatile actor in various malignant diseases. The aim of this study was to further explore the potential clinical significance of DCN in pancreatic cancer, both regarding its dynamics in serum during chemotherapy and its compartmental and cellular distribution in tumour tissue. To this end, repeated on-treatment levels of soluble DCN were measured using proximity extension assay in 124 patients enrolled in a prospective, observational clinical study, inviting patients diagnosed with pancreatic or other pancreatobiliary-type periampullary adenocarcinoma eligible for adjuvant (n = 30) or first-line palliative (n = 94) chemotherapy. Multiplexed immunofluorescence was applied to map DCN and the associated immune landscape in resected tumours. The results showed increasing levels of DCN in serum after initiation of chemotherapy in palliative, but not in adjuvant, patients. A higher rate of change of serum DCN was an independent adverse prognostic factor in both treatment settings. There was no significant association between systemic levels and local DCN expression. Varying expression of DCN was denoted in both tumour cells, immune cells and stroma, but the prognostic significance was mainly assigned to its expression in B cells. In particular, a higher percentage of DCN positive B cells, overall and in interaction with tumour cells, were independent predictors of shorter survival. In summary, this study is the first to demonstrate the potential clinical utility of on-treatment monitoring of systemic DCN in patients with pancreatic cancer. The findings also provide interesting leads for further research into how DCN may interact with the immune microenvironment to promote tumour development and the emergence of chemoresistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.